CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Novo Nordisk
Main (gene editing) focus: Gene therapies and gene editing for the treatment of genetic blood diseases
Company stage: Commercial
Diseases (gene editing): Haemophilia and other severe genetic diseases
Genome editing tool: megaTAL
Funding stage: Public (NASDAQ:NOVO)
Location: Bagsvaerd, Denmark
Website: https://www.novonordisk.dk/
Pipeline: https://www.novonordisk.com/science-and-technology/r-d-pipeline.html
Gene editing partnerships: bluebird bio, SNIPR Biome
Novo Nordisk is a big pharma company, developing therapies within the areas of diabetes, obesity, cardiovascular diseases, blood diseases and liver diseases. The company is mainly involved in the gene-editing space through its partnership with bluebird bio. These two companies have agreed to jointly develop next generation in vivo genome-editing treatments for genetic diseases including haemophilia, using bluebird's proprietary megaTAL gene-editing technology. Novo Nordisk also has a collaboration with microbiome-focused Danish company SNIPR Biome.
